AURIMOD
AURIMOD develops VIVO, a chronic pain wearable using auricular vagus nerve stimulation.
The record
- Vertical
- Devices & Robotics
- Sub-segment
- Chronic pain neuromodulation
- Product type
- Device
- Headquarters
- Vienna, Austria
- Region
- Europe
What they do
Vienna-based AURIMOD is led by founder and CEO Stefan Kampusch, identified by KPMG. Its official site describes VIVO as a Class IIa medical device using auricular vagus nerve stimulation, or aVNS, for chronic pain. VIVO Pal is its accompanying digital pain diary app.
History and progression
How AURIMOD got here, step by step.
11 November 2026
KPMG Global Tech Innovator winner
AURIMOD won the KPMG Private Enterprise Global Tech Innovator 2026 global final in Lisbon. TissueLabs placed second.
Sources
Related companies